Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2013 March;59(1) > Minerva Gastroenterologica e Dietologica 2013 March;59(1):69-87

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

  CUTTING EDGE GASTROENTEROLOGY


Minerva Gastroenterologica e Dietologica 2013 March;59(1):69-87

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Management of non-alcoholic fatty liver disease

Sourianarayanane A. 1, Pagadala M. R. 2, Kirwan J. P. 3

1 Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 2 Pathobiology at Lerner Research Institute and Gastroenterology and Hepatology, Cleveland Clinic, OH, USA; 3 Pathobiology at Lerner Research Institute and Gastroenterology and Hepatology, Cleveland Clinic, OH, USA


PDF  


Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease in the United States. Non-alcoholic steatohepatitis (NASH), the most severe form of NAFLD, has an increased risk for progression to cirrhosis and associated comorbidities such as cardiovascular disease. Metabolic syndrome (MS) including insulin resistance and obesity is central to the development of NASH. Currently there is no definitive treatment for NASH and most of the available treatment options are targeted towards improving various parameters of MS. Treatment of NAFLD includes diet and lifestyle modification, pharmacological interventions and surgical therapies, or a combination of these interventions. This review focuses on the available current and potential future therapies for treating NASH.

top of page

Publication History

Cite this article as

Corresponding author e-mail

kirwanj@ccf.org